Oct 15, 2025 8:00 am EDT bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
Oct 9, 2025 1:00 pm EDT bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
Oct 8, 2025 3:45 pm EDT bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
Oct 7, 2025 8:00 am EDT bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
Sep 26, 2025 8:00 am EDT bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
Sep 17, 2025 8:15 am EDT bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
Sep 9, 2025 8:00 am EDT Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
Sep 3, 2025 8:00 am EDT U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
